Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral rhIL-11 in active Crohn's disease
NCT00040521Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2002
- Primary completion
- Oct 2003
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oprelvekin in Crohn's disease (5 arms), sponsored by Pfizer. Primary endpoint: Clinical Remission (CDAI < 150) at 6 weeks. Started Apr 2002; status: completed.
02
Drugs
oprelvekin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00040521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040521.